OTLK
OUTLOOK THERAPEUTICS INCNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$22.28M
P/E Ratio
—
EPS
$-2.96
Beta
0.19
52W High
$3.39
52W Low
$0.16
50-Day MA
$0.38
200-Day MA
$1.27
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
2.85
PEG Ratio
—
About OUTLOOK THERAPEUTICS INC
Outlook Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. The company is headquartered in Cranbury, New Jersey.
Fundamentals
| Revenue (TTM) | 205,700 |
| Gross Profit (TTM) | $-22.34M |
| EBITDA | $-58.82M |
| Operating Margin | 1116.00% |
| Return on Equity | -3.65% |
| Return on Assets | -209.00% |
| Revenue/Share (TTM) | $0.01 |
| Book Value | $-0.60 |
| Price-to-Book | 38.42 |
| Price-to-Sales (TTM) | 108.33 |
| EV/Revenue | 248.54 |
| EV/EBITDA | -4.13 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 658.00% |
| Shares Outstanding | $104.61M |
| Float | $70.89M |
| % Insiders | 13.02% |
| % Institutions | 6.86% |
Analyst Ratings
Consensus ($4.17 target)
2
Buy1
HoldData last updated: 4/8/2026